Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.
about
Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatmentsStructure-Based Design, Synthesis, and Structure−Activity Relationship Studies of HIV-1 Protease Inhibitors Incorporating PhenyloxazolidinonesSubstrate Envelope-Designed Potent HIV-1 Protease Inhibitors to Avoid Drug ResistanceHIV protease inhibitors: a review of molecular selectivity and toxicityCaenorhabditis elegans as a Model System for Studying Drug Induced Mitochondrial ToxicityHIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites.Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.Determination of Phenotypic Resistance Cutoffs From Routine Clinical DataDendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors.Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitorRecent key advances in human immunodeficiency virus medicine and implications for ChinaNeurological and psychiatric adverse effects of antiretroviral drugs.Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo.Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy.Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavirHIV and HAART-Associated DyslipidemiaThe evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.Boosted protease inhibitors and the electrocardiographic measures of QT and PR durationsRitonavir-induced hepatotoxicity and ultrastructural changes of hepatocytes.Molecular Basis for Drug Resistance in HIV-1 ProteaseTwice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.Pharmacogenetics/genomics and personalized medicine.Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients.Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients.Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies.High prevalence of PI resistance in patients failing second-line ART in Vietnam.Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.The role of cytochrome P450 in antiretroviral drug interactions.The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavirMg supplementation attenuates ritonavir-induced hyperlipidemia, oxidative stress, and cardiac dysfunction in rats.Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Human immunodeficiency virus and its effects on the visual system.HIV protease inhibitors: recent clinical trials and recommendations on use.Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.Ritonavir-boosted protease inhibitors in HIV therapy.Pharmacologic modulation strategies to reduce dose requirements of anticancer therapy while preserving clinical efficacy.
P2860
Q26784261-11893727-BD77-45A9-BB91-A0F3BBBECA52Q27665164-7EC758F4-6D62-46EA-AE7B-83D7FB89E4ADQ27679880-BF96F504-AFCF-4A20-AB89-6AB5E4D78E9CQ28082749-457E7807-742C-4BF4-835C-8C77ED3A2692Q28547224-2DF31F95-E59E-4613-9A77-0EF867FC439EQ30373475-03C6455F-5DC1-48F4-A7ED-AE03CBD78F49Q30603781-E3A280DF-2598-4020-9BBC-A16CFF61D8A1Q31139379-5AFFEE25-3FD7-4120-8E21-A694D4BC6A88Q33604765-D61D83F0-F440-4925-8A22-E6F805D6B702Q33807628-DD196448-FBC2-4061-838C-8DF1529D3D71Q33840412-E8FF1AAD-295C-41DE-81D7-9F59DBC8569CQ33933502-A066FE21-AAF2-4244-961A-79E6CE47D6DCQ34039419-22D0074E-CC68-4FDB-88C5-E9421639265DQ34217770-13E05E5E-ECE7-42B5-961D-915F841E775CQ34718314-B598E1C2-E183-4C69-AA95-BF7934A15F73Q34754376-4689BB59-3C9D-4B70-AA41-590D727597CFQ35002453-7CD9533D-785D-4F3F-99C9-3A806EC92932Q35020217-6808D220-F094-4799-A75C-674F5C707516Q35023687-0F1DA770-F9B6-478A-BCCB-A5269512557EQ35034349-391B501C-7C42-43D3-B0EF-EAF7CC9C8A63Q35216400-3677B8C3-1E49-46DA-A12E-86EE4C67185CQ35260370-85DE2106-7181-4EFB-8049-7A8CA57F50E2Q35674849-9BD9457E-4746-4F07-B513-925F06249365Q36107193-DDD1E325-8B6E-4855-A22E-924B16832FC5Q36294685-27976A5E-2069-4FFB-AB5E-721E798BFD9BQ36315090-8C318825-A67D-4298-A619-4E3B9E92CBBCQ36343716-125FC242-5E87-4910-990D-AB201CD985A4Q36375914-2742449D-2972-4C23-8D0A-BC4437B1C3ACQ36551309-2223349D-B995-440B-AA69-58B49F478A8BQ36876420-86E1A783-BE50-492F-9C41-47ACF7719A39Q36909336-F0449CFB-D694-4EB2-B3B4-CE1ED913EB92Q37193089-6328F295-DEF3-4805-8F5D-CFD4CA99D8AEQ37346036-150BBD3E-41BC-4004-9268-12F9000C7F5DQ37378110-2382E86A-4302-46CE-814A-082AF5FF26EEQ37482057-DA2DBCB9-BD23-46F2-A875-7D2A1853E344Q37519715-DEB20B47-F2A8-4F8B-8908-BD2F4DDC8567Q37598680-D28AFD70-DC09-4EF3-BB2B-9E19D86A206AQ37818237-AEEE3E18-81F4-49CE-A9B4-6BDF5A02B540Q37866319-9AC816B5-37EC-403A-8B47-B19DCFEEE16FQ38024126-023E819B-FD4D-4DD9-A80B-94A7DEE40ACE
P2860
Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pharmacological and therapeuti ...... rapy in HIV-infected patients.
@ast
Pharmacological and therapeuti ...... rapy in HIV-infected patients.
@en
type
label
Pharmacological and therapeuti ...... rapy in HIV-infected patients.
@ast
Pharmacological and therapeuti ...... rapy in HIV-infected patients.
@en
prefLabel
Pharmacological and therapeuti ...... rapy in HIV-infected patients.
@ast
Pharmacological and therapeuti ...... rapy in HIV-infected patients.
@en
P356
P1476
Pharmacological and therapeuti ...... rapy in HIV-infected patients.
@en
P2093
Richard A Petruschke
Robert K Zeldin
P356
10.1093/JAC/DKH029
P407
P577
2003-12-04T00:00:00Z